跳至主要内容
临床试验/NCT00239304
NCT00239304已完成1 期

A Phase I/II Trial of ZD1839 (Iressa) Given Concurrently With Cisplatin and Radiotherapy in Patients With Locally Advanced Head and Neck Cancer

AstraZeneca1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2003年6月最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
AstraZeneca
入组人数
40
试验地点
1
主要终点
Parts 1 and 2: Safety (Incidence of DLTs)

研究概览

简要总结

To determine the safety and tolerability of gefitinib in combination with cisplatin and radiation (3D-CRT or IMRT) in patients with locally advanced head and neck cancer.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Histologically confirmed head and neck cancer
  • Lymph node negative or positive
  • Metastasis negative
  • Chemo- and radiotherapy naïve
  • Measurable disease by RECIST
  • Written informed consent

排除标准

  • Severe alcohol abuse
  • Active ILD
  • Co-existing chronic gastrointestinal disease(s)
  • Brain metastasis

结局指标

主要结局

Parts 1 and 2: Safety (Incidence of DLTs)

Part 3: Safety and tolerability

次要结局

  • Parts 2 and 3: Efficacy (Incidence of complete response at 3 months after the end of trial treatment based on RECIST criteria)
  • Exploratory Outcome: EGFR-1 expression, amplification and activation Serum VEGF levels

研究者

发起方
AstraZeneca
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验